Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:AUPHNASDAQ:SNDXNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.25+0.4%$3.05$2.18▼$7.85$246.85M1.141.76 million shs1.09 million shsAUPHAurinia Pharmaceuticals$8.29-2.0%$8.09$4.71▼$10.67$1.14B1.261.35 million shs862,366 shsSNDXSyndax Pharmaceuticals$13.18-2.8%$14.30$12.06▼$25.07$1.13B0.921.51 million shs913,539 shsSYRESpyre Therapeutics$17.94+1.4%$20.54$16.71▼$40.84$1.08B2.98556,154 shs623,872 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%-6.25%-14.77%-56.14%-68.62%AUPHAurinia Pharmaceuticals0.00%-1.78%+4.28%-9.60%+65.47%SNDXSyndax Pharmaceuticals0.00%-3.87%-15.73%+5.27%-44.62%SYRESpyre Therapeutics0.00%-1.27%-8.93%-20.41%-52.70%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.2687 of 5 stars3.51.00.00.03.51.70.6AUPHAurinia Pharmaceuticals2.9888 of 5 stars3.52.00.00.03.30.81.9SNDXSyndax Pharmaceuticals3.7371 of 5 stars3.52.00.04.43.30.80.0SYRESpyre Therapeutics2.1388 of 5 stars3.60.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$17.25666.67% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5038.72% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$36.20174.66% UpsideSYRESpyre Therapeutics 3.13Buy$50.33180.56% UpsideCurrent Analyst Ratings BreakdownLatest ANNX, SNDX, AUPH, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $41.003/18/2025SYRESpyre TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/4/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.003/4/2025SNDXSyndax PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $42.003/4/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.002/18/2025SYRESpyre TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/13/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.001/8/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AAUPHAurinia Pharmaceuticals$235.13M4.84N/AN/A$2.63 per share3.15SNDXSyndax Pharmaceuticals$23.68M47.88N/AN/A$6.53 per share2.02SYRESpyre Therapeutics$890K1,214.62N/AN/A($0.22) per share-81.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M$0.05N/A14.80N/A-10.23%-4.41%-3.07%5/1/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.73N/AN/AN/AN/A-64.34%-57.72%5/6/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$4.23N/AN/AN/AN/A-210.01%-44.40%5/8/2025 (Estimated)Latest ANNX, SNDX, AUPH, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/A3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 million2/27/2025Q4 2024SYRESpyre Therapeutics-$0.89-$0.81+$0.08-$0.81$2.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18AUPHAurinia Pharmaceuticals0.175.605.11SNDXSyndax PharmaceuticalsN/A6.996.99SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AAUPHAurinia Pharmaceuticals36.83%SNDXSyndax PharmaceuticalsN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%AUPHAurinia Pharmaceuticals4.30%SNDXSyndax Pharmaceuticals4.10%SYRESpyre Therapeutics6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableAUPHAurinia Pharmaceuticals300137.34 million137.02 millionOptionableSNDXSyndax Pharmaceuticals11086.02 million81.86 millionOptionableSYRESpyre Therapeutics10060.26 million48.24 millionOptionableANNX, SNDX, AUPH, and SYRE HeadlinesRecent News About These CompaniesSwiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 30 at 3:25 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's WhyMarch 29 at 11:59 AM | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 28 at 7:15 PM | finanznachrichten.deSpyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Still a Buy?March 28 at 12:41 PM | marketbeat.comNatixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 28 at 3:40 AM | marketbeat.comAptorum Group (NASDAQ:APM) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head SurveyMarch 28 at 2:28 AM | americanbankingnews.comSpyre Therapeutics says first patient dosed in Phase 1 trial of SPY003March 27, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's WhyMarch 27, 2025 | marketbeat.comSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 27, 2025 | prnewswire.comEFG Asset Management North America Corp. Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 27, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - Here's What HappenedMarch 26, 2025 | marketbeat.comEmerald Advisers LLC Acquires 254,222 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 23, 2025 | marketbeat.comCommit To Buy Spyre Therapeutics At $12.50, Earn 13.5% Annualized Using OptionsMarch 21, 2025 | nasdaq.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Coverage Initiated at Wolfe ResearchMarch 19, 2025 | marketbeat.comSpyre Therapeutics initiated with an Outperform at Wolfe ResearchMarch 18, 2025 | markets.businessinsider.comVictory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 15, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by BrokeragesMarch 14, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Should You Buy?March 12, 2025 | marketbeat.comCandriam S.C.A. Has $5.76 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANNX, SNDX, AUPH, and SYRE Company DescriptionsAnnexon NASDAQ:ANNX$2.25 +0.01 (+0.45%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.27 +0.02 (+0.89%) As of 03/28/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Aurinia Pharmaceuticals NASDAQ:AUPH$8.29 -0.17 (-2.01%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.38 +0.09 (+1.03%) As of 03/28/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Syndax Pharmaceuticals NASDAQ:SNDX$13.18 -0.38 (-2.80%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$13.08 -0.10 (-0.79%) As of 03/28/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$17.94 +0.25 (+1.41%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$17.94 0.00 (0.00%) As of 03/28/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
